<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577278</url>
  </required_header>
  <id_info>
    <org_study_id>05149</org_study_id>
    <secondary_id>P01CA030206</secondary_id>
    <secondary_id>CHNMC-05149</secondary_id>
    <secondary_id>CDR0000579136</secondary_id>
    <secondary_id>NCI-2010-01230</secondary_id>
    <nct_id>NCT00577278</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a
      donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's
      immune system from rejecting the donor's stem cells. When the stem cells from a related donor
      that do not exactly match the patient's blood, are infused into the patient, they may help
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
      Sometimes the transplanted cells from a donor can also make an immune response against the
      body's normal cells. Giving tacrolimus and sirolimus before and after transplant may stop
      this from happening.

      PURPOSE: This phase II trial is studying the side effects and how well giving indium In 111
      ibritumomab tiuxetan and yttrium y 90 ibritumomab tiuxetan together with rituximab,
      fludarabine, melphalan, and donor stem cell transplant works in treating patients with B-cell
      non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To evaluate the safety and efficacy of a preparative regimen of
      Yttrium-90 (90^Y)- labeled anti-cluster of differentiation (CD)20 monoclonal antibody (MAb)
      (yttrium Y 90 ibritumomab tiuxetan) in combination with fludarabine (fludarabine phosphate)
      and melphalan followed by allogeneic hematopoietic stem cell transplant (APBSCT) for
      treatment of patients with B-cell low-grade non-Hodgkin lymphoma (LG NHL), intermediate-grade
      non-Hodgkin lymphoma (IG NHL) and mantle cell lymphoma (MCL). II. To evaluate the short- and
      long-term complications of this new preparative regimen, including rates of engraftment,
      acute and chronic graft-versus-host-disease (GVHD) and infectious complications. III. To
      estimate the disease response rate, disease relapse (progression) rate, and non-relapse
      mortality rate. IV. To perform exploratory studies that seek to measure/characterize the
      expression of costimulatory molecules and impact of these molecules on the natural killer
      (NK) and T cells of a subset of lymphoma patients pre- post- allogeneic stem cell transplant
      (ASCT) and the stem cell product from a portion of sibling donors.

      OUTLINE: REDUCED-INTENSITY CONDITIONING: Patients receive rituximab intravenously (IV)
      followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV
      followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also
      receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4.

      STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV or orally (PO) and sirolimus PO beginning on
      day -3 and continuing for up to 6 months with taper.

      After completion of study treatment, patients are followed up every 3 months for 1 year and
      then every 6 months for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 15, 2007</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse/progression rate</measure>
    <time_frame>At 2 years</time_frame>
    <description>Confidence intervals will be established by calculating the exact 95% confidence limits for a binomial parameter. The product-limit method of Kaplan and Meier will be utilized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>5 years from transplant</time_frame>
    <description>The product-limit method of Kaplan and Meier will be utilized. Will consider univariate Cox models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years from transplant</time_frame>
    <description>The product-limit method of Kaplan and Meier will be utilized. Will consider univariate Cox models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity and safety of treatment regimen</measure>
    <time_frame>5 years after transplant</time_frame>
    <description>Will be summarized in terms of type, severity (by National Cancer Institute [NCI] Common Toxicity Criteria [CTC] and nadir or maximum values for the laboratory measure) and time of onset. Analyses will be conducted to evaluate acute and chronic GVHD and infectious complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years from transplant</time_frame>
    <description>The product-limit method of Kaplan and Meier will be utilized. Will consider univariate Cox models.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years from transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression (TTP)</measure>
    <time_frame>5 years from transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>5 years from transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>Rapamune</other_name>
    <other_name>rapamycin</other_name>
    <other_name>SLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo APBSCT</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 ibritumomab tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>IDEC-In2B8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
    <other_name>90Y ibritumomab tiuxetan</other_name>
    <other_name>IDEC Y2B8</other_name>
    <other_name>Y90 Zevalin</other_name>
    <other_name>Y90-labeled ibritumomab tiuxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative Studies</description>
    <arm_group_label>Treatment (chemo, monoclonal antibody therapy, transplant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6/6/human leukocyte antigen (HLA) matched sibling donor or related donor, or
             acceptable matched unrelated donor

          -  Biopsy (Bx) proven diagnosis of LG (including small lymphocytic lymphoma [SLL]/chronic
             lymphocytic leukemia [CLL], lymphoplasmacytic lymphoma, marginal zone,
             mucosa-associated lymphoid tissue [MALT] lymphoma and follicular lymphoma [FL] grade 1
             and 2), IG (FL grade 3 and DLCL) or MCL NHL

          -  Prior demonstrated monoclonal CD20+ malignant B-Cell population in lymph nodes and/or
             BM Bx specimen

          -  LG NHL; must have relapsed after achieving a complete response (CR) or partial
             response (PR) to prior therapy or have never responded to prior therapy, including
             chemotherapy and/or MAb therapy

          -  MCL NHL in any disease state

          -  Other aggressive B-cell lymphomas (excluding Burkitt lymphoma or Burkitt-like
             lymphoma) having had at least one relapse or having been refractory to chemotherapy

          -  Bone marrow (BM) aspiration and Bx ( =&lt; 42 days prior to imaging dose) which show &lt;
             25% lymphomatous involvement of total cellularity; in CLL, peripheral lymphocyte count
             &lt; 5000/mm^3

          -  Salvage chemotherapy/MAbs to reduce BM lymphomatous involvement and reduce disease
             bulk allowed

          -  Normal renal function test with serum creatinine of =&lt; 1.5 mg/dl, or a creatinine
             clearance of &gt;= 60 ml/min

          -  Adequate pulmonary function as measured by forced expiratory volume in one second
             (FEV1) &gt; 65% of predicted measured, or a diffusing capacity of carbon monoxide (DLCO)
             &gt;= 50% of predicted measured

          -  Cardiac Ejection fraction of &gt; 50% by Echocardiogram (ECHO) or multi gated acquisition
             (MUGA)

          -  Adequate liver function tests with a bilirubin of =&lt; 1.5 x normal and serum glutamic
             oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) =&lt; 2 x
             normal

          -  Negative Human Immunodeficiency Virus (HIV) antibody

          -  Karnofsky Performance Status (KPS) &gt; 80

          -  No active Central Nervous System (CNS) disease or prior history of CNS disease

          -  Involved field External Beam Therapy (EBT) to area excluding lung, heat, liver, and
             kidney allowed, but evaluated on a case-by-case basis

          -  Recovery from last therapy and therapy dose (Y-90 Zevalin) must be &gt;= 4 weeks from
             prior systemic chemotherapy

          -  DONOR: Age &lt; 75 years

          -  DONOR: HLA genotypically identical related donor or acceptable matched unrelated donor

          -  DONOR: Must consent to G-CSF administration and leukapheresis for matched sibling
             donor, but for unrelated donor, the donor will sign a standard consent for donation at
             their designated donor or collection center

          -  DONOR: Must have adequate veins for leukapheresis or agree to placement of a Central
             Venous Catheter (CVC [femoral, subclavian])

        Exclusion Criteria:

          -  Presence of Human Anti-Zevalin Antibody (HAZA)

          -  Prior radioimmunotherapy (RIT)

          -  Prior AHSCT; but prior aHSCT is allowed; prior fractionated total body irradiation
             (FTBI) in the conditioning regimen will be evaluated on an individual basis

          -  Prior malignancy, except for: adequately treated basal cell or squamous cell skin
             cancer; adequately treated noninvasive carcinomas; or other cancer from which the
             patient has been disease-free for at least 5 years; myelodysplastic syndromes (MDS) is
             excluded from this criterion

          -  Active evidence of Hepatitis B or C infection; hepatitis B surface antigen positive

          -  Total peripheral lymphocyte count &gt; 5,000/mm^3 if SLL/CLL

          -  Burkitt lymphoma or Burkitt-like lymphoma

          -  DONOR: Age &lt; 12 years

          -  DONOR: Identical twin

          -  DONOR: Pregnancy

          -  DONOR: HIV infection

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to G-CSF

          -  DONOR: Current serious systemic illness or any disease that may preclude the use of
             G-CSF (eg, recent thromboembolic event); for unrelated donors, considered ineligible
             by National Marrow Donor Program (NMDP) donor evaluation center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auayporn P. Nademanee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

